Rocket Pharmaceuticals (RCKT) News Today $6.53 +0.62 (+10.49%) Closing price 04:00 PM EasternExtended Trading$6.52 0.00 (-0.08%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Rocket Lab Stock Is Ripping Higher Tuesday: Here's WhyApril 15 at 4:08 PM | benzinga.comInsider Buying: Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) CEO Purchases 20,000 Shares of StockApril 15 at 4:12 AM | insidertrades.comRocket Pharmaceuticals CEO buys $101.6K in common stockApril 15 at 1:43 AM | msn.comFranklin Resources Inc. Sells 1,076,785 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Franklin Resources Inc. lessened its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 62.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 653,559 shares of the biotechnology company's stock after sellinApril 12 at 4:30 AM | marketbeat.comVanguard Group Inc. Purchases 1,040,655 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Vanguard Group Inc. raised its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 18.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,577,595 shares of the biotechnology company's stockApril 12 at 3:39 AM | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)Needham & Company LLC restated a "buy" rating and issued a $42.00 target price on shares of Rocket Pharmaceuticals in a research note on Wednesday.April 11, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider Buys $99,165.30 in StockApril 11, 2025 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives $43.00 Consensus Price Target from BrokeragesApril 11, 2025 | americanbankingnews.comAaron Ondrey Sells 7,489 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) StockRocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) CFO Aaron Ondrey sold 7,489 shares of the stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $5.29, for a total transaction of $39,616.81. Following the transaction, the chief financial officer now owns 129,650 shares in the company, valued at $685,848.50. The trade was a 5.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.April 10, 2025 | marketbeat.comRocket Pharmaceuticals Out Of Orbit, But Ready For RelaunchApril 10, 2025 | seekingalpha.comRocket Pharmaceuticals appoints new Chief OfficerApril 10, 2025 | uk.investing.comRocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 1-Year Low - Here's WhyRocket Pharmaceuticals (NASDAQ:RCKT) Hits New 52-Week Low - Here's What HappenedApril 9, 2025 | marketbeat.comRocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will TripleApril 9, 2025 | insidermonkey.comADAR1 Capital Management LLC Acquires 207,100 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)ADAR1 Capital Management LLC increased its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 4,816.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 211,400 shares of the biotechnologApril 9, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) CFO Sells $39,616.81 in StockApril 9, 2025 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by ExodusPoint Capital Management LPExodusPoint Capital Management LP boosted its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 189.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 189,879 shares of the biotechnology company'April 9, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eleven have given a buApril 9, 2025 | marketbeat.comOvata Capital Management Ltd Buys Shares of 200,000 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Ovata Capital Management Ltd purchased a new position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 200,000 sharesApril 7, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Acquired by Schroder Investment Management GroupSchroder Investment Management Group increased its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 76.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 413,550 shares of the biotechnology cApril 7, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Trading 4.5% Higher - Here's What HappenedRocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Up 4.5% - Here's What HappenedApril 4, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Purchased by Wellington Management Group LLPWellington Management Group LLP lifted its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 24.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,995,177 shares of the biotechApril 4, 2025 | marketbeat.comPictet Asset Management Holding SA Sells 68,736 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Pictet Asset Management Holding SA lessened its stake in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,317,969 shares of theApril 3, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 52-Week Low - Here's WhyRocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week Low - Time to Sell?April 2, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 15.6% - What's Next?Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 15.6% - Time to Sell?April 1, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week Low - What's Next?Rocket Pharmaceuticals (NASDAQ:RCKT) Hits New 52-Week Low - What's Next?March 27, 2025 | marketbeat.comEFG Asset Management North America Corp. Has $1.83 Million Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)EFG Asset Management North America Corp. trimmed its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 40.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 145,629 sharMarch 27, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 6.1% - Should You Sell?Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 6.1% - What's Next?March 26, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $8.25 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Charles Schwab Investment Management Inc. raised its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 15.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 656,090 shares ofMarch 24, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Holdings Boosted by Privium Fund Management B.V.Privium Fund Management B.V. grew its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 34.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 397,650 shares of the biotechnologMarch 20, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Down - What's Next?Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Down - Time to Sell?March 19, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 4.5% - Here's What HappenedRocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Down 4.5% - Should You Sell?March 18, 2025 | marketbeat.comone8zero8 LLC Makes New Investment in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)one8zero8 LLC purchased a new stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 39,700 shares of the biotechnology company's stock, valued at approximately $499,March 17, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Get Free Report) have been given an average rating of "Moderate Buy" by the twelve research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and eleven have assigned aMarch 14, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Up - Should You Buy?Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Up - Still a Buy?March 13, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Coverage Initiated by Analysts at BMO Capital MarketsBMO Capital Markets started coverage on Rocket Pharmaceuticals in a report on Wednesday. They set an "outperform" rating and a $50.00 target price for the company.March 13, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 52-Week Low - Here's What HappenedRocket Pharmaceuticals (NASDAQ:RCKT) Hits New 12-Month Low - What's Next?March 12, 2025 | marketbeat.comRocket Pharmaceuticals initiated with an Outperform at BMO CapitalMarch 11, 2025 | markets.businessinsider.comWhat is Chardan Capital's Estimate for RCKT FY2025 Earnings?Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Investment analysts at Chardan Capital lifted their FY2025 EPS estimates for Rocket Pharmaceuticals in a research note issued on Sunday, March 2nd. Chardan Capital analyst Y. Livshits now expects that the biotechnology company will post eMarch 6, 2025 | marketbeat.comRocket Pharmaceuticals, Inc. (RCKT): A Bull Case TheoryMarch 6, 2025 | msn.comTorray Investment Partners LLC Raises Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)Torray Investment Partners LLC grew its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 66.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 122,095 shares of the biotechnology company's stock after purchMarch 4, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week Low After Analyst DowngradeRocket Pharmaceuticals (NASDAQ:RCKT) Hits New 12-Month Low Following Analyst DowngradeMarch 3, 2025 | marketbeat.comScotiabank Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) StockScotiabank boosted their target price on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Monday.March 3, 2025 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Given New $15.00 Price Target at The Goldman Sachs GroupThe Goldman Sachs Group cut their target price on Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating on the stock in a research report on Monday.March 3, 2025 | marketbeat.comRocket Pharmaceuticals price target lowered to $36 from $39 at CanaccordMarch 3, 2025 | markets.businessinsider.comRocket Pharmaceuticals (RCKT) Gets a Buy from J.P. MorganMarch 3, 2025 | markets.businessinsider.comCanaccord Genuity Group Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock PriceCanaccord Genuity Group decreased their price target on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating for the company in a research note on Monday.March 3, 2025 | marketbeat.comBrokers Issue Forecasts for RCKT FY2029 EarningsRocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Stock analysts at Wedbush issued their FY2029 earnings per share estimates for Rocket Pharmaceuticals in a research note issued to investors on Friday, February 28th. Wedbush analyst Y. Zhong expects that the biotechnology company will poMarch 3, 2025 | marketbeat.comWhat is William Blair's Estimate for RCKT Q1 Earnings?Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Research analysts at William Blair issued their Q1 2026 earnings estimates for Rocket Pharmaceuticals in a research report issued on Thursday, February 27th. William Blair analyst S. Corwin expects that the biotechnology company will postMarch 3, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for RCKT Q2 Earnings?Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for shares of Rocket Pharmaceuticals in a report released on Thursday, February 27th. Leerink Partnrs analyst M. Foroohar expects that the biotechnology compMarch 3, 2025 | marketbeat.comRocket Pharmaceuticals Rings the Opening BellMarch 2, 2025 | nasdaq.com Remove Ads Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKT Media Mentions By Week RCKT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCKT News Sentiment▼1.100.80▲Average Medical News Sentiment RCKT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCKT Articles This Week▼216▲RCKT Articles Average Week Remove Ads Get Rocket Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACAD News Today IBRX News Today APLS News Today TWST News Today MLTX News Today AMRX News Today RXRX News Today VCEL News Today MIRM News Today SDGR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RCKT) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RCKT Stock Free RCKT Stock Alerts